SLP Simulations Plus Inc

Quarterly Revenues Up 15%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).

2QFY19 highlights compared with 2QFY18:

• Net revenues increased 15%, or $1.1 million, to $8.5 million from $7.4 million
• Gross profit was $6.3 million, up $1.0 million, or 19.5%, from $5.2 million
• SG&A was $2.8 million, up $470,000, or 20%, from $2.3 million
• SG&A as a percentage of revenues increased to 33.2% from 31.8%
• R&D expense increased 49.5%, or $240,000, to $724,000 from $484,000
• Income before taxes increased 13.0%, or $311,000, to $2.7 million from $2.4 million
• Net income decreased $1.4 million, or 39.6%, to $2.1 million from $3.5 million
  • This decrease is mainly due to the Company recording in the prior year (2QFY18) a $1.5 million one-time adjustment to deferred taxes based on the Tax Cuts and Jobs Act passed in the prior fiscal year

• Diluted earnings per share decreased $0.07, to $0.12 from $0.19 per share; without the effect of the tax adjustment, the change would have been an increase of $0.01 per share as the prior years’ tax benefit effected diluted earnings per share by approximately $0.08 per share

6moFY19 highlights compared with 6moFY18:

• Net revenues increased 11%, or $1.6 million, to $16.0 million from $14.4 million
• Gross profit was $11.6 million, up $1.0 million, or 9.7%, from $10.6 million
• SG&A was $5.5 million, an increase of $782,000, or 16.5%, from $4.7 million
• R&D expenditures were $1.3 million, an increase of $409,000, or 48.3%, over $845,000
• Income before taxes decreased 3.8%, or $184,000, to $4.7 million from $4.9 million
• Net income decreased $1.6 million, or 30.0%, to $3.6 million from $5.2 million
  • This decrease is mainly due to the Company recording in the prior year (2QFY18) a $1.5 million one-time adjustment to deferred taxes based on the Tax Cuts and Jobs Act in 2018
• Diluted earnings per share decreased $0.09, to $0.20 from $0.29 per share; approximately $0.08 per share of the decrease is associated with the prior years’ tax benefit recorded in 2QFY18. Without the effect of the tax adjustment, the change would have been a decrease of $0.01 per share as the prior years’ tax benefit effected diluted earnings per share by approximately $0.08 per share

Shawn O’Connor, chief executive officer of Simulations Plus, said: “As expected, our revenue growth accelerated in the second quarter, in line with historical seasonality and benefiting from double-digit growth in consulting services. This progress reinforced our confidence in our full-year revenue growth outlook of 10-15%, and this does not yet benefit from the ongoing investments in sales and marketing initiatives designed to drive future growth. In particular, we are adding to our consulting services team in an effort to address the growing demand and expanding opportunities we see in the marketplace.”

John Kneisel, chief financial officer of Simulations Plus, added: “Second quarter pretax earnings increased 13% over the prior year. Net income was down compared to the prior year due nearly entirely to the non-recurring $1.5 million tax benefit recorded in the prior year, which boosted the comparable period’s net income.”

Quarterly Dividend Declared

The Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock payable on May 1, 2019, to shareholders of record as of April 24, 2019. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.

Investor Conference Call

The Company has announced an investor conference call that will be webcast live at 1:15 p.m. PDT/4:15 p.m. EDT on Tuesday, April 9, 2019. The live webcast/teleconference will be accessible by registering here. Please dial in five to ten minutes prior to the scheduled start time. A live, listen-only webcast will also be available by dialing (415) 930-5321, and entering access code 271-105-468. A replay of the webcast will be available at the Investors section of the Simulations Plus website following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of our new software products as well as improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn

  SIMULATIONS PLUS, INC.       CONDENSED CONSOLIDATED BALANCE SHEETS As of February 28, 2019 and 2018   (Unaudited) (Audited) February 28,   August 31, ASSETS

2019

2018

Current assets Cash and cash equivalents 9,893,953 $ 9,400,701 Accounts receivable, net of allowance for doubtful accounts of $0 6,227,555 5,514,528 Revenues in excess of billings 2,264,518 1,985,596 Prepaid income taxes - 312,593 Prepaid expenses and other current assets   518,512   610,439 Total current assets 18,904,538 17,823,857 Long-term assets Capitalized computer software development costs, net of accumulated amortization of $11,708,089 and $11,095,903 4,779,575 5,152,594 Property and equipment, net 302,977 335,224 Intellectual property, net of accumulated amortization of $3,484,168 and $3,019,584 5,490,833 5,905,416 Other intangible assets net of accumulated amortization of $1,031,250 and $852,500 3,458,750 3,637,500 Goodwill 10,387,198 10,387,198 Other assets   37,227   37,227 Total assets $ 43,361,098 $ 43,279,016   LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable 289,762 $ 351,605 Accrued payroll and other expenses 1,135,579 1,152,176 Income taxes payable 106,845 - Current portion - Contracts payable 1,750,000 2,556,644 Billings in excess of revenues 958,948 384,603 Deferred revenue   891,650   381,928 Total current liabilities 5,132,784 4,826,956   Long-term liabilities Deferred income taxes,net 2,814,535 3,195,139 Payments due under Contracts payable   1,660,672   3,334,296 Total liabilities 9,607,991 11,356,391   Commitments and contingencies $ - $ -   Shareholders' equity Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding $ - $ - Common stock, $0.001 par value 50,000,000 shares authorized 17,499,958 and 17,416,445 shares issued and outstanding 7,501 7,417 Additional paid-in capital 14,435,574 13,453,668 Retained earnings   19,310,032   18,461,540 Total shareholders' equity   33,753,107 $ 31,922,625

 

 

 

Total liabilities and shareholders' equity $ 43,361,098 $ 43,279,016

 

  SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the three and six months ended February 28, 2019 and 2018       Three months ended   Six months ended (Unaudited) (Unaudited)

2019

 

2018

2019

 

2018

  Revenues $ 8,471,720 $ 7,356,714 $ 16,007,623 $ 14,425,496 Cost of revenues   2,207,831     2,115,483     4,406,952     3,851,090   Gross margin   6,263,889     5,241,231     11,600,671     10,574,406   Operating expenses Selling, general, and administrative 2,809,691 2,339,721 5,530,093 4,748,237 Research and development   724,034     484,329     1,253,670     845,146   Total operating expenses   3,533,725     2,824,050     6,783,763     5,593,383     Income from operations   2,730,164     2,417,181     4,816,908     4,981,023     Other income (expense) Interest income 5,573 6,180 9,245 10,489 Interest expense (38,188 ) (38,188 ) (76,376 ) (76,658 ) Miscellanous income - - - - Gain (loss) from sale of assets - - - - Loss on currency exchange   (1,916 )   (585 )   (32,526 )   (13,262 ) Total other income (expense)   (34,531 )   (32,593 )   (99,657 )   (79,431 )   Income before provision for income taxes 2,695,633 2,384,588 4,717,251 4,901,592 Provision for income taxes   (596,184 )   1,090,198     (1,081,855 )   289,198   Net Income $ 2,099,449   $ 3,474,786   $ 3,635,396   $ 5,190,790     Earnings per share Basic $ 0.12 $ 0.20 $ 0.21 $ 0.30 Diluted $ 0.12 $ 0.19 $ 0.20 $ 0.29   Weighted-average common shares outstanding Basic 17,476,603 17,302,763 17,449,069 17,292,391 Diluted 18,002,741 17,855,351 17,984,078 17,843,345  

View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005373/en/

Simulations Plus Investor RelationsMs. Renee Bouche, 661-723-7723renee@simulations-plus.com

Hayden IRMr. Cameron Donahue651-653-1854cameron@haydenir.com